Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Supplement May Lower CVD Risk in People of Low Birth Weight

By Drug Discovery Trends Editor | December 10, 2014

(Gabriela Pinto/Flickr CC)

A simple supplement could be a safe and cost-effective way of reducing heart disease in individuals born with a low birth weight, suggests research from the University of Cambridge. The study, carried out in rats, also raises the possibility of developing a blood test to indicate how much damage there is in the aortas of these individuals.

Researchers at the Institute of Metabolic Science fed low birth weight rats a supplement of the molecule co-enzyme Q (CoQ) and found that in those rats that grew quickly after birth, the supplement prevented cells in the aorta from ageing prematurely, which can lead to heart disease. Scientists have known for some years that babies with a low birth weight who grow quickly are more likely to develop heart disease than those with a normal birth weight. This new study, published in The FASEB Journal, has identified a novel mechanism underlying this phenomenon and suggests a possible treatment.

Researchers funded by the British Heart Foundation and the Medical Research Council (MRC) fed pregnant rats either a control diet or a low protein, high carbohydrate diet. The mothers fed the low protein diet had pups with a low birth weight, but which grew quickly when suckled by a control-fed mother. When the researchers examined the aorta from these rats, they found that their cells had aged more quickly than those from the normal birth weight offspring and that this was associated with a deficit in CoQ in the aorta.

When the researchers gave the low birth weight rats extra CoQ in their diet after weaning, they found that this prevented the accelerated aging of and damage to their aortas. CoQ is produced naturally in the body and is required to ensure that the mitochondria – the cells’ ‘batteries’ – work properly and to protect cells from oxidative stress caused by highly reactive molecules known as free radicals, which can cause damage to proteins, membranes and genes.

The team also found that CoQ is reduced in white blood cells from low birth weight offspring and hence that levels of CoQ in the blood cells can be used to see how much damage there is in the aorta.

“Our study has answered a question that has puzzled doctors for some time now – why children of low birth weight who grow quickly are prone to heart disease in later life,” explains Professor Susan Ozanne from the MRC Metabolic Diseases Unit, who led the study. “We believe it’s because they are deficient in co-enzyme Q. As this molecule is also then deficient in the individual’s blood cells, it may be possible to develop a simple blood test capable of diagnosing the amount of damage to their aorta and therefore likely to develop heart disease.”

Dr Jane Tarry-Adkins, first author on the study, adds: “Although our study is only in rodents, it may one day have major implications for both the prevention and early treatment of heart disease. It suggests that it may be possible to treat at-risk individuals with a safe and cost-effective supplement that has the potential to prevent heart disease before they display any symptoms of the disease.”

Globally, cardiovascular disease is responsible for more deaths than any other disease, claiming an estimated 17.3 million lives in 2008, a number which is predicted to grow to over 23.3 million by 2030. Reliable, early diagnostic tests for cardiovascular disease risk could help reduce this burden. The researchers plan to establish whether their findings can be confirmed in humans and therefore make their prognostic potential a realistic possibility.

Source: University of Cambridge


Filed Under: Drug Discovery

 

Related Articles Read More >

S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response
Drug companies sign “Most Favored Nation” deals, then raise prices anyway
New gonorrhea antibiotic could treat resistant infections
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE